Lu177-PSMA therapy for men with advanced prostate cancer: 18 months survival analysis in a single Australian tertiary institution.

Annaleis Tatkovic Rhiannon McBean David Wong

Published in: Journal of medical imaging and radiation oncology (2021)

Our study reported an 18-month overall survival of 64% in patients with mCRPC who have undergone LuPSMA therapy. Our study identified that baseline serum PSA, SUVmax and biochemical response to treatment are prognostic markers for increased overall survival.

Keyphrases

prostate cancer
radical prostatectomy
free survival
stem cells
computed tomography
mesenchymal stem cells
positron emission tomography